The health care institution also placed first on the state-specific “Best Hospital” lists in Minnesota, Arizona and Florida.
Health Care + Med Tech
Dr. Farrugia will officially take over as the head of Mayo Clinic at the start of next year. Current president and CEO Dr. John Noseworthy, in the meantime, will be preparing him for the role.
The Minneapolis-based startup will use the National Institute of Mental Health grant toward further development of its wearable device that treats impulsive behaviors.
Nothing has been confirmed yet, but a report from Axios indicates the Minnesota-based insurance giant will buy Washington-based pharmacy company Genoa Health.
The National Science Foundation sees commercialization potential in the University of Minnesota’s “synthetic incompatibility” process that can target certain mosquito populations.
The Minneapolis startup has raised $240 million and keeps growing.
Company also inks deal to co-develop laser device to treat arterial disease.
Former U.S. Senate Majority Leader Bill Frist and James Carville and Mary Matalin are on the roster for MANOVA.
The University of Minnesota’s Office for Technology Commercialization is offering the algorithm for licensing opportunities.
The Eden Prairie-based company specializing in brain issue detection is in the midst of a hefty fundraising campaign. The first investment was obtained early this month, with more than $9 million more to go toward its target.
Miromatrix, Superior Organoid, and MNPHARM each landed $100,000 regenerative medicine awards.
The company is working towards clinical trials for its implantable kidney and liver products.
A collaboration between Mayo and Exact Sciences is yielding accurate blood DNA tests for treatable cases.
The deal will seek to commercialize the Preparing Heart and Mind educational app for parents of babies with heart defects.
Noaber Foundation led a $1.5 million venture round for the digital health platform.
Craig Samitt will officially join the nonprofit health insurance provider at the end of July.
The move from California to Minnesota comes as the chronic lower back pain device maker has wrapped a $58 million fundraising round.
The deal continues a string of transactions by Bio-Techne over the last five years and marks its foray into the diagnostics area of cancer medicine.